FDA halts marketing of certain unapproved narcotics
Executive SummaryNine companies received FDA warning letters March 31 for manufacturing 14 unapproved narcotic drugs including high concentrate morphine sulfate oral solutions and immediate release tablets containing morphine sulfate, hydromorphone or oxycodone. The companies cited include Boehringer Ingelheim Roxane; Cody Laboratories; Glenmark Pharmaceuticals; Lannett Company; Lehigh Valley Technologies; Mallinckrodt; Physician's Total Care; Roxane Laboratories; and Xanodyne. The warning letters were sent as part of FDA's initiative on marketed unapproved drugs (1"The Pink Sheet," June 12, 2006, p. 10)
You may also be interested in...
US court tosses Teva suit seeking generic Restasis exclusivity. FTC loses appeal challenging Shire's citizen petitions, settles Solvay pay-for-delay case. DoJ resolves FCA case alleging company made deal to avoid paying FDA user fees for two NDAs.
Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.